VERAMORPH LLC — National Science Foundation SBIR Phase I: BM
VERAMORPH LLC — SBIR Phase I award from National Science Foundation.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from National Science Foundation in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $225,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code BM links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $225,000
- Agency
- National Science Foundation
- Program / Phase
- SBIR · Phase I
- Topic
- BM
- NAICS
- —
- Place of performance
- DE
- Period
- 2020-08-01 → 2021-07-31
Description
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve the efficacy of drug products through a novel tablet. Current formulation technologies have limited compatibility with the estimated 6